What's "New" at FDA?
This article was originally published in RPM Report
Executive Summary
Amarin, biosimilars and why FDA’s low point was even lower than you thought.
You may also be interested in...
Much “Ado” About Biosimilars
The approval of Kadcyla gives Roche/Genentech yet another new breakthrough cancer therapy in the US. It also offers some clues about the future of biosimilars at FDA.
Are The 90s Back? Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High
With 45 new molecular entities and novel biologics cleared in 2012, FDA approvals have reached a level not seen since the mid-1990s, the golden age of modern medicine. The group reflects a boom in oncology; other drug development trends like orphan diseases and personalized medicine held steady. Big pharma contributed just over a third of the 2012 class, with Pfizer regaining the lead with five novel approvals.
Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High
With 45 new molecular entities and novel biologics cleared in 2012, FDA approvals have reached a level not seen since the mid-90s, the golden age of modern medicine. The group reflects a boom in oncology; other drug development trends like orphan diseases and personalized medicine held steady. Big pharma contributed just over a third of the 2012 class, with Pfizer regaining the lead with five novel approvals.